Skip to main content

Senzime

Senzime AB is a Swedish medical technology company that develops and markets quantitative neuromuscular monitoring systems for surgical patient safety. The company designs and manufactures advanced monitoring instruments and disposable sensors, including the TetraGraph system, used to measure neuromuscular blockade during general anesthesia. Its products are deployed in hospital operating rooms and intensive care units to help clinicians optimize muscle relaxation recovery and prevent post-operative complications. Revenue is derived from direct product sales of monitoring devices, software licenses, and recurring sales of single-use disposable sensors to hospitals globally. Senzime holds an emerging position in advanced surgical patient monitoring technologies. The company is headquartered in Uppsala, Sweden, and its shares trade on the Nasdaq First North Growth Market.

4 of the funds FundTelligence covers report a position in Senzime.

Legal name
Senzime AB
Sector
Health Care
Country
Sweden
Funds holding it
4

Funds holding Senzime

Loading...